In response to the market demand, Indian drugmakers, including Cipla, are actively developing generic versions of these weight-loss drugs to secure a larger market share in India, which is the world's most populous country.
May 13, 2024
As India and Nepal grapple with the growing burden of cancer cases, initiatives like these are pivotal in steering the healthcare landscape towards innovative solutions and improved patient care
Nov 04, 2023
The integration of KIMS into the QCIL network marks a new chapter in the healthcare landscape. The increased bed capacity and the solid financial outlook indicate a promising future for Quality Care under Blackstone's ownership, solidifying its role as a major player in the healthcare sector.
Oct 26, 2023
Manipal HealthMap highlighted that the acquisition will expand its footprint by adding 23 new centres to its Manipal TRUtest network. This network, post-acquisition, will comprise over 100 centers, serving a vast customer base exceeding 50 lahks across 16 states.
Oct 19, 2023
$1 billion of the $1.915 billion total will be donated by the World Bank to help India's health sector prepare for pandemics and improve the delivery of healthcare services. Two complementary loans totaling $500 million each make up the $1 billion loans.
Jul 08, 2022
Medicircle unleashes VROZART Health in delivering top-class services in the health care sector. VROZART Health brings healthcare at ease which helps you choosing treatments as per your ease and convenience
Aug 06, 2021
Interchangeable Designation Allows Substitution at the Pharmacy Counter for Lantus Across the U.S. to Help Increase Access to Medicines for People Living with Diabetes
Jul 29, 2021
Interchangeable Designation Allows Substitution at the Pharmacy Counter for Lantus Across the U.S. to Help Increase Access to Medicines for People Living with Diabetes
Jul 29, 2021
“Numerous studies have shown long-term survival improvements with the Opdivo plus Yervoy combinationacross various tumor types, bringing benefit to patients around the world".
Jul 17, 2021
As discussed during our Capital Markets Day in February, simplifying the CHC product portfolio is an important part of our strategy to focus our resources and efforts where we can bring the most value, especially to consumers.
Jul 14, 2021
In a two-stage approach, the study will initially investigate the efficacy of a vaccine formulation targeting the original virus strain (D.614), while a second stage will evaluate a second formulation targeting the Beta variant (B.1.351)
Jul 09, 2021
2-DG is yet another addition to our COVID-19 portfolio that already covers the full spectrum of mild to moderate and severe conditions and includes a vaccine. We are extremely pleased to have partnered with DRDO in our collective fight against the COVID-19 pandemic.
Jun 28, 2021
2-DG is yet another addition to our COVID-19 portfolio that already covers the full spectrum of mild to moderate and severe conditions and includes a vaccine. We are extremely pleased to have partnered with DRDO in our collective fight against the COVID-19 pandemic.
Jun 28, 2021
“We look forward to the European Commission’s decision as we build on our innovative multiple myeloma and cell therapy research to offer novel and personalized treatment options for patients in need.â€
Jun 25, 2021
Recommendation based on positive results from the Phase 3 CheckMate -577 trial in which Opdivo doubled disease-free survival compared to placebo in the all-randomized population
Jun 25, 2021
This approval follows a priority review designation by the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) and marks the first global regulatory approval for the oral, potent, and highly selective MET tyrosine kinase inhibitor
Jun 23, 2021
Brovana® is a long-acting beta-2 adrenergic agonist (beta-2 agonist) indicated for treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Jun 23, 2021
"By combining enzalutamide, which has a proven clinical benefit in men with metastatic castration-sensitive prostate cancer, with talazoparib, our PARP inhibitor that is active in DDR-mutated cancer, we may be able to offer a new treatment option that targets the underlying genetic mechanisms associated with DDR-mutated mCSPC.â€
Jun 23, 2021
Halozyme’s drug delivery technology provides the opportunity to administer large volume subcutaneous injections that may enable dosing intervals of every three months and up to six months or longer for ViiV’s pipeline of HIV medicines
Jun 22, 2021
The approval confirms Aubagio as the first oral multiple sclerosis (MS) therapy for first-line treatment of children and adolescents with MS in the European Union.
Jun 19, 2021
It is important to note that tofacitinib has not been approved or authorized for use by any regulatory authority worldwide for the treatment of COVID-19 and tofacitinib should not be used in patients with an active serious infection.
Jun 17, 2021
Testosterone Topical Solution USP, 30 mg per pump actuation is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone
Jun 17, 2021
By virtue of the settlement, NATCO and Breckenridge have been granted a license permitting the launch of their generic carfilzomib products on a date that is held as confidential in the year 2027 or sooner depending on certain occurrences.
Jun 14, 2021
Molnupiravir, the antiviral drug was initially developed for the treatment of influenza and is repurposed to completely suppress the COVID virus transmission within 24 hours.
Jun 11, 2021
“The positive evidence from the CADENZA trial demonstrate significant improvements in hemolysis and meaningful impact on key measures of anemia and fatigue.â€
Jun 11, 2021
These doses are part of Pfizer and BioNTech’s previously announced pledge to provide two billion doses of the COVID-19 vaccine to low- and middle-income countries over the next 18 months.
Jun 10, 2021
“In addition to this agreement with the U.S. government, we are actively engaged in numerous efforts to make molnupiravir available globally to fulfill Merck’s commitment to widespread access†said Rob Davis, president, Merck.
Jun 09, 2021
In 2018, the FDA approved LORBRENA for the treatment of patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease
Mar 05, 2021
While the pseudovirus system used is a surrogate for authentic SARS-CoV-2, previous studies have shown excellent concordance between pseudotype neutralization and SARS-CoV-2 neutralization assays.
Jan 21, 2021
GSK plc announced updated data from GARNET cohort F evaluating dostarlimab in mismatch repair-deficient non-endometrial advanced solid cancers being presented today at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Jan 18, 2021
“This collaboration with Jubilant Therapeutics will further advance our comprehensive research efforts to find therapeutics to diminish cytokine storms and decrease COVID-19 symptom gravity,†said Yulia Nefedova.
Jan 16, 2021
Through PBGI, Pfizer is investing up to $500 million in biotechnology companies, providing funding and access to Pfizer’s scientific expertise to help ensure the continuity of promising clinical development programs of potential future strategic interest to Pfizer.
Jan 13, 2021
“Today’s authorisation is a really important milestone towards enabling children to have access to age-appropriate formulations of HIV medicine," said Deborah Waterhouse, CEO of ViiV Healthcare
Jan 13, 2021
Vir Biotechnology, Inc. and GlaxoSmithKline plc today announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in Phase 1b/2a clinical trial
Jan 12, 2021
Merck announced the U.S. FDA accepted for priority review a Biologics License Application for V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease.
Jan 12, 2021
The application includes data for a new, 50 mg tablet that can be dispersed in water and which was developed to facilitate use in children, who are disproportionately affected by the disease.
Jan 08, 2021
Empagliflozin and Metformin Hydrochloride Extended-Release (ER) Tablets, are indicated as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin hydrochloride is appropriate.
Jan 07, 2021
AstraZeneca’s COVID-19 vaccine has been granted emergency use authorization in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the active immunization of adults.
Jan 07, 2021
Pfizer inc. and OPKO Health Inc. announced today that the USFDA has accepted for filing the initial Biologics License Application for somatrogon, a long-acting human growth hormone for the treatment of pediatric patients with growth hormone deficiency.
Jan 05, 2021
“The EMA’s decision to validate our application represents important progress for the esophageal cancer community, and we look forward to potentially bringing Opdivo to patients in the EU who may benefit.â€
Jan 05, 2021
Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms
Jan 02, 2021
LORBRENA is a third-generation ALK inhibitor specifically developed to inhibit the most common tumour mutations that drive resistance to current medications and to address brain metastases
Dec 29, 2020
“With these 100 million additional doses, the United States will be able to protect more individuals and hopefully end this devastating pandemic more quickly,†said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.
Dec 24, 2020
“We are excited to partner with Menarini for Ryaltris™ across Europe as they have a proven track record in partnering and commercializing respiratory products in the region, " said Achin Gupta, Executive Vice President, Business Head EMEA-L, Glenmark Pharmaceuticals
Dec 23, 2020
"Building upon the promising clinical findings to date for MK-7110, Merck is pleased to be collaborating with the U.S. Government to advance the manufacture and distribution of this candidate for patients with serious COVID-19 disease," said Dr. Roger M. Perlmutter, president, Merck Research Lab.
Dec 23, 2020
“Glioblastoma is an aggressive cancer with a very poor prognosis that has seen limited new treatment options over the last 15 years,†said Michael Mandola, Ph.D., Oncology Development Program Lead, Bristol Myers Squibb.
Dec 23, 2020
This authorization represents the first time people living with HIV in Europe may be able to receive a long-acting injectable treatment that removes the need to take daily oral tablets
Dec 21, 2020
BENLYSTA is the first medicine approved to treat systemic lupus and adults with active lupus nephritis, an important treatment advance for patients with this incurable autoimmune disease.
Dec 18, 2020
This new dosing option is consistent with the approved Imfinzi dosing in extensive-stage small cell lung cancer and once approved, will be available to patients with locally advanced, unresectable NSCLC weighing more than 30kg.
Dec 15, 2020
Phase 2 trials in 1,200 adults, young children, and infants suggest new poliovirus vaccine may have the potential to overcome outbreaks caused by a mutated polio strain linked to the oral vaccine that typically circulates in areas of low immunisation coverage, and poses one of biggest barriers to eradication
Dec 12, 2020
“Patients in Europe with MSI-H/dMMR colorectal cancer have had only chemotherapy-containing regimens available to them in the first-line treatment setting and have historically faced poor outcomes,†said Dr. Vicki Goodman.
Dec 11, 2020
The FDA’s acceptance of our application for 20vPnC is yet another significant milestone in Pfizer’s continuing efforts to help protect adults against pneumococcal disease,†said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research and Development, Pfizer.
Dec 09, 2020
"We believe JBI-802 could one day serve as a powerful therapeutic agent for the treatment of specific cancers, including myelodysplastic syndrome, select acute myeloid leukemia and solid tumor subsets.â€
Dec 08, 2020
We continue to be encouraged by the findings from this Phase 1/2 study, which now include durable factor VIII expression through one year of follow-up, and we look forward to continuing to follow these patients
Dec 07, 2020
PureTech’s global, randomized, double-blind, placebo-controlled Phase 2 trial is designed to evaluate the efficacy, safety and tolerability of LYT-100 in adults with post-acute COVID-19 respiratory complications
Dec 05, 2020
Objective of the study is to assess the efficacy of Carragelose nasal and throat spray in reducing the rate, severity, and duration of COVID-19 infections
Dec 01, 2020
The Alliance is a collaborative network of leading cancer centers that work together to advance comprehensive cancer profiling and establish standards of care for molecular testing in oncology through research
Dec 01, 2020
Atopic dermatitis is a chronic inflammatory disease of the skin that can be debilitating, and severe disease can significantly impact many aspects of life for both children and their families.
Nov 30, 2020
Hon'ble Prime Minister's leadership vision, in-depth understanding and knowledge of the facts guided us in facilitating the interactions and discussions on the vaccines and therapeutics for COVID-19
Nov 30, 2020
DJSI is one of the world’s most respected and widely accepted sustainability benchmarks globally with only the top-ranked companies in terms of Corporate Sustainability within each industry featured in the index.
Nov 26, 2020
Senhwa announces multiple IND application submissions to US FDA and Health Canada evaluating its investigational drug, CX-5461, for the treatment of patients with solid tumours with BRCA2 or PALB2 mutations
Nov 26, 2020
Piramal Sarvajal, the safe drinking water initiative of Piramal Foundation launched a tool named Composite Water Vulnerability Index at its recent Webinar on ‘Sustainable Water Security for Urban Under-Served’.
Nov 25, 2020
The vaccine's clinical study not only provides key data for the launch of the vaccine in China, but also may play a positive role in the widespread promotion and use of the vaccine throughout Asia and around the world
Nov 25, 2020
The oral antiviral medication Favipiravir, which prevents the replication phase of the virus life-cycle, leads to significant improvement in clinical cure in patients with mild to moderate COVID-19.
Nov 23, 2020
“The results from the CROWN trial demonstrate that LORBRENA has the potential to be a practice-changing, first-line option, and we thank the many people and their families who participated in this trial.â€
Nov 19, 2020
The approval was based on the results of Phase III and Phase II clinical studies conducted globally to evaluate Fycompa as an adjunctive therapy in pediatric patients with POS or PGTCS
Nov 16, 2020
This initiative supports pharmaceutical companies by providing them for free with the necessary tools to protect COVID-19 relevant medicines and vaccines against counterfeiting
Nov 13, 2020
Thursday, October 03, 2024